Eversept Partners’s Ocular Therapeutix OCUL Stock Holding History

Eversept Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-150,000	Closed	-$2.13M	–	116
2021 Q2	$2.13M	Buy	+150,000	New	+$2.28M	0.14%	66

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Eversept Partners's OCUL Position: Q3 2021 in Review

Eversept Partners sold out of Ocular Therapeutix (OCUL) in Q3 2021, closing a stake of 150,000 shares — an estimated $2.13M sold.

Eversept Partners first reported a position in OCUL in Q2 2021 and held it in 1 quarter. The position peaked at $2.13M in Q2 2021. 141 funds tracked by Wall St. Rank hold OCUL as of Q3 2021.

Eversept Partners reported no remaining Ocular Therapeutix position as of Q3 2021 after selling out during the quarter.
Eversept Partners sold 150,000 Ocular Therapeutix shares in Q3 2021, an estimated $2.13M.
Eversept Partners first reported a position in Ocular Therapeutix in Q2 2021 and held it in 1 quarter.
Eversept Partners's Ocular Therapeutix position peaked at $2.13M in Q2 2021.
141 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2021.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.